{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:29:44Z","timestamp":1787671784550,"version":"build-2736575974"},"reference-count":25,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Relapse is the predominant cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) in FLT3 gene internal tandem duplication (FLT3-ITD)\u2013mutated acute myeloid leukemia (AML). Although measurable residual disease (MRD) is increasingly used for risk stratification, optimal FLT3-ITD MRD assessment, the prognostic value of peritransplant MRD dynamics, and their implications in transplant-related decision-making remain unclear. We conducted a multicenter, retrospective study of 219 patients with FLT3-ITD\u2013mutated AML in morphologic complete remission at transplantation, assessing peritransplant MRD by polymerase chain reaction (PCR)\u2013next-generation sequencing (NGS). Pretransplant MRD positivity (\u22650.001% by PCR-NGS) was associated with inferior outcomes vs MRD negativity (2-year relapse-free survival [RFS], 56.8% vs 86.5%; cumulative incidence of relapse, 30.0% vs 6.9%; overall survival, 65.9% vs 88.4%; all P&amp;lt; .001). Peritransplant MRD dynamics outperformed single time point assessments, identifying patients at high risk such as those with post-HCT MRD conversion. Post-HCT FLT3 inhibitor maintenance independently improved RFS (P = .003), with greatest benefit observed in patients who were MRD-positive. These findings support PCR-NGS\u2013based molecular MRD assessment to refine risk stratification and guide individualized transplant strategies in FLT3-ITD\u2013mutated AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020264","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T22:56:53Z","timestamp":1781045813000},"page":"5607-5619","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Peritransplant molecular MRD monitoring by targeted NGS in patients with\n                    <i>FLT3<\/i>\n                    -ITD\u2013mutated acute myeloid leukemia"],"prefix":"10.1182","volume":"10","author":[{"given":"Xiaoxia","family":"Hu","sequence":"first","affiliation":[{"name":"1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqian","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Jiang","sequence":"additional","affiliation":[{"name":"1State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Fan","sequence":"additional","affiliation":[{"name":"5Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-219X","authenticated-orcid":false,"given":"Yi","family":"Luo","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Ye","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4618-354X","authenticated-orcid":false,"given":"Jiehan","family":"Liang","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"6Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongzheng","family":"Zheng","sequence":"additional","affiliation":[{"name":"7Shanghai Tissuebank Precision Medicine Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"5Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Bone Marrow Transplantation Center of the First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, HangZhou, China"},{"name":"3Institute of Hematology, Zhejiang University, Hangzhou, China"},{"name":"4Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"12","key":"2026082510512617300_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2026082510512617300_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026082510512617300_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","article-title":"Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia","volume":"22","author":"Oran","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026082510512617300_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.21147\/j.issn.1000-9604.2025.04.04","article-title":"Impact of clinical characteristics and genetic profiles on outcomes of allogeneic stem cell transplantation with sorafenib maintenance in FLT3-ITD acute myeloid leukemia patients: a multi-center, retrospective study","volume":"37","author":"Zhao","year":"2025","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"2026082510512617300_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12967-024-05114-w","article-title":"Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML\/MDS: a multicenter retrospective study","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"issue":"26","key":"2026082510512617300_bib6","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026082510512617300_bib7","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-021-01131-6","article-title":"Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)","volume":"35","author":"Patkar","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2026082510512617300_bib8","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"2026082510512617300_bib9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026082510512617300_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026082510512617300_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.2023.8650","article-title":"DNA sequencing in adults with acute myeloid leukemia to detect residual disease prior to hematopoietic cell transplant","volume":"330","author":"Khaire","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"2026082510512617300_bib12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.leu.2403846","article-title":"Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia","volume":"19","author":"Noguera","year":"2005","journal-title":"Leukemia"},{"issue":"22","key":"2026082510512617300_bib13","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026082510512617300_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"23","key":"2026082510512617300_bib15","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"issue":"19","key":"2026082510512617300_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2026082510512617300_bib17","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"JCO"},{"issue":"22","key":"2026082510512617300_bib18","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2026082510512617300_bib19","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2026082510512617300_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/bloodadvances.2024014672","article-title":"Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia","volume":"9","author":"Joudinaud","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"2026082510512617300_bib21","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ajh.70053","article-title":"Cytomolecular mechanisms of relapse and post-relapse outcomes after frontline FLT3 inhibitor-based therapy in FLT3 -mutated AML","volume":"100","author":"Arora","year":"2025","journal-title":"Am J Hematol"},{"issue":"12","key":"2026082510512617300_bib22","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026082510512617300_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2026082510512617300_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"2026082510512617300_bib25","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5607\/2537918\/blooda_adv-2026-020264-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/16\/5607\/2537918\/blooda_adv-2026-020264-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:52:07Z","timestamp":1787669527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/16\/5607\/569046\/Peritransplant-molecular-MRD-monitoring-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":25,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020264","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,25]]},"published":{"date-parts":[[2026,8,14]]}}}